New York, June 13, 2026, 15:06 (EDT)
- Pfizer finished Friday at $26.21, edging up 0.15%. The S&P 500 picked up 0.5% on the day. Pfizer’s dividend yield was about 6.56%.
- Drug-pricing policy in Germany is now in focus. Bulls still point to Pfizer’s dividend, confirmed 2026 outlook and cancer and obesity pipeline.
Pfizer Inc. closed Friday at $26.21, up 4 cents. About 38.77 million shares changed hands. Market cap came in near $149.38 billion. Gains were small against the major indexes. The S&P 500 added 0.5%, Dow rose 0.7%, and Nasdaq was up 0.3%. The Health Care Select Sector SPDR ETF dropped 0.18%. Pfizer still outperformed its sector benchmark.
Drug pricing in Europe is back in focus for investors. Germany’s health minister, Nina Warken, said drug companies won’t be left out of upcoming cost cuts, telling reporters, “Every sector must play its part in this reform.” That comment came after a Reuters story said Pfizer CEO Albert Bourla told Chancellor Friedrich Merz the company is “reviewing our external engagements as well as the timing, scope and future prioritization” of some planned investments in Germany. For stocks, the story is simple: shares go up on hopes for better profits or less risk, and drop when rules, failed trials, or weaker pricing hit cash flow. Reuters
EU court adviser rejects Commission’s vaccine contract appeal; Pfizer faces new investor questions A European legal twist adds to the post-COVID drag but isn’t an immediate earnings alarm. An adviser to Europe’s top court said the European Commission’s appeal over more public disclosure of COVID-19 vaccine deals—including contracts with Pfizer and BioNTech—should be tossed. That’s key for Pfizer, since its COVID franchise is well off the highs, and investors are already pressing management on how it will rebuild sales in oncology, obesity, and specialty drugs.
Pfizer turned in a solid Q1 2026, with revenue up 5% to $14.45 billion. Stripping out Comirnaty and Paxlovid, revenue rose 7% operationally, while new and acquired products jumped 22% operationally. The company held onto its full-year revenue target of $59.5 billion to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00. Adjusted EPS strips out amortization, deals, and other major items. The dividend remains a key factor, too: Pfizer’s board set a $0.43 second-quarter dividend for June 12, marking its 350th consecutive quarterly dividend.
Pfizer bulls are pointing to new pipeline headlines. The FDA cleared broader use of Pfizer’s HYMPAVZI drug, now approved for more hemophilia A and B groups, including kids as young as six. Pfizer also showed Phase 2b results for berobenatide, its possible monthly GLP-1 receptor agonist. These GLP-1 drugs target blood sugar and appetite, and are central to current obesity research. Pfizer plans 10 Phase 3 studies for berobenatide in 2026 within a 20-plus trial push in obesity.
Pfizer still has to show its pipeline can make up for pricing headwinds, patent cliffs and shrinking COVID sales, the bears say. Q1 adjusted diluted EPS dropped 18% year over year even as revenue rose, so better sales haven’t fixed earnings or margins yet. On obesity, Pfizer is taking a once-monthly shot strategy, which could set it apart, but Reuters said analysts are focused on side effects to see if it can work in the market. In the VESPER-3 trial, about 38% had nausea and 23.3% had vomiting, numbers that JPMorgan’s Chris Schott flagged as investor red lines.
Pfizer trades at a price that gives it an income tilt but not a low-risk profile. The shares change hands at roughly 9 times the midpoint of 2026 adjusted EPS guidance. The trailing P/E sits at around 20, and the dividend yield stands at 6.56%. Those P/E and dividend yield figures set the backdrop for how investors look at profit and payouts. Wall Street analysts see a 12-month target near $29.05. Out of 23 analysts, 8 rate it a buy, 13 have it on hold, and 2 say sell, so the consensus gives room for upside but isn’t lopsidedly bullish.
Pfizer’s next big event is its Q2 earnings report set for August 4, 2026, when Wall Street looks for EPS of $0.68. Investors are focused on whether the company will stick to its 2026 outlook, any signs that European pricing pressure could shake up capital spending, and if updates in obesity and oncology are enough to shift Pfizer’s story from value play to possible rebound.
